Skip to the page

Data / Drug companies / GLP-1 Receptor Agonist

GLP-1 Receptor Agonist drugs: 9 drugs from 15 companies in the FDA NDC directory

GLP-1 Receptor Agonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 123 products in this class from 15 companies, covering 9 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on April 27, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

  • 15Companies
  • 123Products
  • 9Drugs by generic name

Drugs in the GLP-1 Receptor Agonist class

Ranked by number of companies that list the drug.

DrugProducts hereCompanies listing it
Liraglutide2211
Tirzepatide542
Semaglutide182
Dulaglutide112
Exenatide42
Oral semaglutide61
Orforglipron61
Insulin degludec and liraglutide11
Insulin glargine and lixisenatide11

Companies with the most products in this class

CompanyProductsMain dosage formsMain marketing categoryNewest product started
Eli Lilly and Company58injection, solution; tablet, film coatedNew drug applications (NDA)April 1, 2026
Novo Nordisk23injection, solution; tabletNew drug applications (NDA)April 27, 2026
A-S Medication Solutions22injection, solution; injectionNew drug applications (NDA)January 22, 2026
Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)3injection, solutionGeneric drugs (ANDA)December 24, 2024
Amneal Pharmaceuticals LLC2injectionGeneric drugs (ANDA)November 22, 2024
AstraZeneca Pharmaceuticals LP2injectionNew drug applications (NDA)December 12, 2014
Biocon Pharma Inc.2injection, solution; injectionGeneric drugs (ANDA)April 25, 2026
Cipla USA Inc.2injection, solutionGeneric drugs (ANDA)February 25, 2026
Orbicular Pharmaceutical Technologies Private Limited2injection, solutionGeneric drugs (ANDA)February 26, 2026
Teva Pharmaceuticals, Inc.2injection, solution; injectionGeneric drugs (ANDA)August 28, 2025
Hikma Pharmaceuticals USA Inc.1injectionGeneric drugs (ANDA)December 24, 2024
Lupin Pharmaceuticals, Inc.1injectionGeneric drugs (ANDA)October 2, 2025
Meitheal Pharmaceuticals Inc.1injectionGeneric drugs (ANDA)April 2, 2025
NorthStar RxLLC1injectionGeneric drugs (ANDA)March 1, 2026
Sanofi-Aventis U.S. LLC1injection, solutionBiologics (BLA)November 21, 2016

Dosage forms

Dosage formProductsShare
Injection, solution9375.6%
Injection1411.4%
Tablet108.1%
Tablet, film coated64.9%

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.